Skip to Content
MilliporeSigma
All Photos(1)

Documents

ADD621C

Sigma-Aldrich

HepaRG Maintenance and Metabolism Medium Supplement

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352207
NACRES:
NA.71

form

liquid

shipped in

dry ice

storage temp.

−20°C

General description

Biopredic′s HepaRG Maintenance and Metabolism Medium Supplement with Antibiotics can be used with all HepaRG cell lines. See user guide for detailed protocols.

Legal Information

Use of this product is subject to one or more license agreements.

HepaRG cells are patented and their use is strictly limited; consider the cells as a single use, disposable product that must be destroyed upon conclusion of a study or experiment. Propagating, reproducing, cloning, subcloning or any other use of the cells following the conclusion of a study is prohibited. Use of the cells to produce or manufacture commercial products for general sale or for use in the manufacture of products intended for general sale is prohibited. Transfer of the cells to anyone not employed within the same organization, whether for financial benefit or not, is prohibited. If you are unwilling to accept the terms of this LIMITED USE LICENSE, do not ORDER or use them, and immediately return the cells for credit. Violators of this Limited Use License will be prosecuted to the fullest extent of the law.
HepaRG is a trademark of BioPredic International company

Storage Class

10 - Combustible liquids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

An Automated Multiplexed Hepatotoxicity and CYP Induction Assay Using HepaRG Cells in 2D and 3D.
Ott, et al.
SLAS discovery, 22, 614-625 (2017)
Catherine C Bell et al.
Drug metabolism and disposition: the biological fate of chemicals, 45(4), 419-429 (2017-02-01)
Reliable and versatile hepatic in vitro systems for the prediction of drug pharmacokinetics and toxicity are essential constituents of preclinical safety assessment pipelines for new medicines. Here, we compared three emerging cell systems-hepatocytes derived from induced pluripotent stem cells, HepaRG
Maxime Demazeau et al.
International journal of pharmaceutics, 524(1-2), 268-278 (2017-04-04)
In this study, we evaluated cationic liposomes prepared from diether-NH
Lindsey M Ott et al.
SLAS discovery : advancing life sciences R & D, 22(5), 614-625 (2017-03-28)
Drug-induced liver injury (DILI) and drug-drug interactions (DDIs) are concerns when developing safe and efficacious compounds. We have developed an automated multiplex assay to detect hepatotoxicity (i.e., ATP depletion) and metabolism (i.e., cytochrome P450 1A [CYP1A] and cytochrome P450 3A4
Takafumi Tomida et al.
Journal of applied toxicology : JAT, 37(3), 382-390 (2016-08-03)
The approach for predicting the degree of drug-induced liver injury (DILI) risk was investigated quantitatively in a modified multiparametric assay using HepaRG cells. Thirty-eight drugs were classified by DILI risk into five categories based on drug labels approved by the

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service